Inference of personalized drug targets via network propagation

Ortal Shnaps, Eyal Perry, Dana Silverbush, Roded Sharan*

*Corresponding author for this work

Research output: Contribution to journalConference articlepeer-review


We present a computational strategy to simulate drug treatment in a personalized setting. The method is based on integrating patient mutation and differential expression data with a protein-protein interaction network. We test the impact of in-silico deletions of different proteins on the flow of information in the network and use the results to infer potential drug targets. We apply our method to AML data from TCGA and validate the predicted drug targets using known targets. To benchmark our patient-specific approach, we compare the personalized setting predictions to those of the conventional setting. Our predicted drug targets are highly enriched with known targets from DrugBank and COSMIC (p < 10-5), outperforming the non-personalized predictions. Finally, we focus on the largest AML patient subgroup (~30%) which is characterized by an FLT3 mutation, and utilize our prediction score to rank patient sensitivity to inhibition of each predicted target, reproducing previous findings of in-vitro experiments.

Original languageEnglish
Pages (from-to)156-167
Number of pages12
JournalPacific Symposium on Biocomputing
StatePublished - 2016
Event21st Pacific Symposium on Biocomputing, PSB 2016 - Big Island, United States
Duration: 4 Jan 20168 Jan 2016


Dive into the research topics of 'Inference of personalized drug targets via network propagation'. Together they form a unique fingerprint.

Cite this